New Issue: Barclays prices $300,000 8.3% reverse convertibles linked to Quest Diagnostics

New York, Aug. 22 - Barclays Bank plc priced $300,000 of 8.3% reverse convertible notes due Aug. 23, 2012 linked to Quest Diagnostics Inc. shares, according to a 424B2 filing with the Securities and Exchange Commission.

The payout at maturity will be par in cash unless Quest Diagnostics shares fall below the protection price of $35.26, 75% of the initial price of $47.01, during the life of the notes and finish below the initial price in which case the payout will be 21.27207 shares of Quest Diagnostics stock.

Barclays Capital is the agent.

Issuer:	Barclays Bank plc
Issue:	Reverse convertible notes
Underlying stock:	Quest Diagnostics Inc. (Symbol: DGX)
Amount:	$300,000
Maturity:	Aug. 23, 2012
Coupon:	8.3%, payable monthly
Price:	Par
Payout at maturity:	Par in cash unless Quest Diagnostics shares fall below the protection price of $35.26, 75% of the initial price, and finish below the initial price, in which case 21.27207 shares of Quest Diagnostics stock
Initial price:	$47.01
Protection price:	$35.26, 75% of $47.01
Exchange ratio:	21.27207
Pricing date:	Aug. 18
Settlement date:	Aug. 23
Agent:	Barclays Capital
Cusip:	06741JML0

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.